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Abstract
Bovine anaplasmosis is an infectious non-contagious disease transmitted mainly by ticks
or fomites contaminated with Anaplasma marginale. Once cattle have developed the dis-
ease it can be treated with antibiotics or chemotherapy, although with partial success. Still,
there is no effective and global prophylactic method available, mainly because of variabil-
ity and diversity showed by different A. marginale strains distributed worldwide. In this
regard, several proteins have been proposed as immunogens, MSPs, OMPs, Type IV
Secretion System Proteins and some other hypothetical proteins, which have been chosen
either by experimental evidence or more recently by genome-based analysis. So far, the
results suggest that a single molecule will not be enough to trigger a protective immune
response in the host, so it is necessary to identify other proteins or epitopes with adequate
immunological properties, a process in which omics tools have potential. In order to
develop a vaccine against bovine anaplasmosis, it has been proposed by the use of
combinations of molecules, exposure formats and application protocols to provide an
effective control of the disease.
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1. Introduction
Tick-borne diseases are considered a major obstacle and the cause of great economic impact for
livestock production [1]. Control measures currently available for tick-borne diseases include
the use of acaricides for reduction or tick populations, specific chemotherapy, chemoprophy-
laxis, controlled exposure and vaccination. These measures limit losses caused by ticks and the
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diseases they transmit [2]. Globally, the most important rickettsial disease in cattle is bovine
anaplasmosis caused by Anaplasma marginale [3].
Vaccination is the method of choice for preventing infectious diseases. In the case of bovine
anaplasmosis, while there are live vaccines, these pose many risks, including: (i) spread of
other blood-borne pathogens, such as Babesia spp. and virus-like bovine leukemia virus to
mention a few [4]; (ii) standardization of vaccine dose; (iii) maintenance of carrier animals;
(iv) quality control and production; (v) maintenance and transportation of vaccines to the end
user, including the need of a cold chain [5, 6].
Inactivated vaccines based on the use of the extracted bacteria while effective, are restricted
due to: (i) potential contamination with erythrocyte membrane antigens; (ii) wide antigenic
variation between Anaplasma strains [7]; (iii) possible short-term immunity; and (iv) ameliora-
tion of clinical signs while not preventing infection, so the animals remain carriers for the rest
of their lives [8].
Vaccine design is compounded by the large antigenic and genetic diversity found in strains
from a region to another, within the same herd and even within the same animal [9, 10].
Current investigations focus on the search for new alternatives for designing vaccines and
diagnostic assays [11–13]. In this review, besides discussing some fundamental aspects of
anaplasmosis, we focus on the molecular characteristics that make A. marginale capable to
persist in nature including: (i) the mechanisms of evasion of the host’s immune response; (ii)
diversity; (iii) hypervariability of some of its components; or (iv) replication.
2. The causal agent
Anaplasma marginale is a tick-borne pathogen and the causative agent of bovine anaplasmosis
[14]. A. marginale is classified in the Rickettsial order, reorganized into two families such as
Anaplasmataceae and Rickettsiaceae [15]. Anaplasma organisms are obligate intracellular
Gram-negative rickettsia, found exclusively within vacuoles derived from the erythrocyte
membrane, and are membrane-bound within the cytoplasm of the host cell. A. marginale
persist in nature in mammalian and ticks hosts, which serve as reservoirs of infection [16]. In
the bovine, A. marginale infect erythrocytes and endothelial cells [17]. The infection process in
endothelial cell has not been described and it is considered as of no relevance within the
persistence mechanisms for the rickettsia [18]. Ticks transmit rickettsia from the salivary
glands during feeding (Figure 1), and within the erythrocyte, the rickettsia replicates by binary
fission to form 8–12 initial bodies and exit from the erythrocyte does not involve destruction of
the host’s cell [19]. Once out of the host cell, the initial bodies invade new erythrocytes in
endless cycles. Ticks acquires the rickettsia while feeding on carrier hosts. In the tick, the
rickettsia infects midgut cells, where there is a first cycle of replication and from here dense
forms move to other tissues. After several rounds of replication, dense forms travel to the
salivary glands where the rickettsia is transmitted to a new mammalian host [16, 20].
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Many species of ticks have been implicated in the transmission of A. marginale, although
Dermacentor andersoni is the most studied of all [16]. Recent studies have focused on the role
of ticks Rhipicephalus (Boophilus) microplus as vectors of bovine anaplasmosis, an issue
discussed below [21, 22].
The first A. marginale sequenced genome published [23] present a very complete description of
the known features to that date. Up to now, there are at least 2 full genome sequences
published (St. Maries and Florida), other 2 almost complete sequences, and 10 more partially
annotated sequences (NCBI/Genome). Comparative studies with the available genome
sequences have been carried out with very interesting results as far as the study of hypervar-
iable genes/antigens [24], while other genome/transcriptome analysis have focused on the
transmission phenotype genes involved [25].
In this chapter, we will review the information available, since the publication of the St. Maries
genome to the specific genes that have been studied as vaccine candidates. Vaccination against
bovine Anaplasmosis traditionally relied on attenuated [5, 26] and inactivated organisms [6, 27].
Both of these types of vaccines will, in most cases, induce a degree of immunity, which do not
prevent infection. There are a number of examples of experimental vaccines, but in this review
only those cases where there has been modification of the organism or recombinant antigens are
included as vaccine candidates will be discussed.
2.1. Major surface proteins as vaccine candidates
Over the last 30 years, six neutralization-sensitive membrane-exposed proteins were originally
reported in 1984 [28, 29] and later named Major Surface Proteins [30]. This group of proteins
has been the subject of a great number of studies aimed at developing a vaccine.
Figure 1. Proposed life cycle of A. marginale in bovine. Modified from [20].
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Msp1 is a heterodimer composed by Msp1a (100 kDa) and Msp1b (105 kDa) joined in a non-
covalent manner and are exposed on the surface of A. marginale [31]. Details of the genetics,
structure, and composition of these two peptides have been described elsewhere [24]. Msp1a is
coded by a single gene and its product is composed of a variable number of tandem-repeat
units of 28–32 aa in length at the amino terminus. The carboxyl end is conserved and extends
mostly as an intracellular domain [32]. Msp1b is coded by a multigene family that expresses
several variants during the acute and chronic phases of the infection [33]. Msp1 is an adhesin
toward erythrocytes and tick-gut cells whereas Msp1b only toward bovine erythrocytes
[34, 35]. It is now known that the adhesion function in Msp1a is located in the variable region
which is composed of several short amino acid sequences (repeats). Analysis of Msp1a repeats
from different isolates has shown no association between tick-transmission capabilities and the
type or number of repeats present within this variable region [36]. Repeat sequences though
have been used for defining genotypes associated to other markers such as the pseudogenes
present in Msp2 [37] or distinguishing genotypes in cattle superinfected with two or more
different Anaplasma strains [10, 38, 39].
Bioinformatic analysis carried out with Msp1a amino acid sequence have shown that Msp1a
variable region is rich in highly immunogenic B cell epitopes, yet these sequences are consid-
ered distracters to the immune system of the host, despite the fact specific monoclonal anti-
bodies neutralize infection to both the erythrocytes and tick cells [40]. Msp1a also contains Th1
cell epitopes in the carboxyl conserved region, which may be involved in immunoprotection
[41]. Initial immunization experiments with recombinant Msp1a showed that autologous
immunity was afforded; yet heterologous immunity was poor [42]. In a semi-controlled exper-
iment where Msp1a was used as marker for matching the vaccine strain and the local strain in
an inactivated vaccine trial in the field, which resulted in partial immunity except when the
challenge was carried with the autologous strain but not when challenge was carried with
heterologous Msp1a-matched strains [7].
More recently, two epitopes, STSSQL (Am1), located within the consensus sequence of the
repeat and SEASTSSQLGA (Am2), which is located in C-terminal end of the 28-aa repetitive
motif of the MSP1a protein, were identified using phage display technology for identification
of immunodominant epitopes recognized by a neutralizing monoclonal antibody against
MSP1a; these peptides were recognized by many but not all healthy infected animals tested
by ELISA assay [43]. These synthetic peptides were conjugated to bovine serum albumin and
used for immunization of mice, which the authors claim were infected with A. marginale was
achieved. Details of the challenge strain used in this experiment are absent [44] and there have
been no follow-up articles using the same peptides in cattle.
The inclusion of Msp1a or its “conserved epitopes” should be carried with caution as the
diversity of this marker is wider in regions where the tick vector is R. microplus than in its
absence [10, 45]. Vaccination based on Msp1a epitopes is further confounded by the fact that
the Msp1a variable region may contain one or several repeats which may include the same or
different repeats and that there are more than 300 repeats reported [45, 46] and this number is
bound to increase as the number of epidemiology studies is published. Furthermore, the
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number of Msp1a-distinct strains (up to nine) within the same herd or even within the same
animal [10, 47, 48] complicates even more the design of an effective vaccine.
While the adhesion function of Msp1a protein is located on the variable region, number or type
of different Msp1a repeat sequences has not been associated with tick-transmission phenotype
[49, 50]. Repeat sequences though have been used for defining genotypes associated to other
markers such as the pseudogenes present in Msp2 [37] or distinguishing genotypes in cattle
superinfected with two or more different Anaplasma strains [10, 38, 39].
As for Msp1b, initial experiments indicated that it was a poor immunogen [51, 52]. Further
evidence indicates that immunization of naive calves with a recombinant fraction containing
the Msp1a-T cell epitopes linked to recombinant Msp1b1, induced a much greater antibody
titer to Msp1b than what was previously observed [52, 53].
DNA vaccines based on either one of Msp1a or Msp1b have given disappointing results. In an
early effort using a construction pVCL/MSP1a for the immunization of mice and cattle [54], a
predominant IgG1 antibody pattern was observed in the two immunized calves. No challenge
was performed, however, as it has been proven, an IgG2 response is necessary in order to
achieve protection [11, 55]. In a similar study with an Msp1b DNA construct, immunization
not only did not induce immunity but immunized animals developed more severe clinical
disease than controls [56]. These latter authors did not test for the type of immunoglobulin
induced by vaccination.
Further studies with DNA vaccines constructs which included bovine herpes virus 1 tegument
protein, BVP22 domain and an invariant-chain major histocompatibility complex class II-
targeting motif capable of enhancing dendritic cell antigen uptake and presentation were fused
to a sequence encoding a B and T cell antigen from the A. marginale Msp1a [57, 58]. This
approach included the intradermal inoculation with a mixture of 2 mg of DNA encoding the
molecular adjuvants bovine FLT3L and GM-CSF to recruit DCs to the intradermal immuniza-
tion site, the results of this experiment were very encouraging as they stimulated the desired
type of immune response with rapid recall of antibody production over a reasonable period
after a single immunization. This study, however, suffers of several flaws (i) the inoculation in
different points of the dendritic cells stimulant and the vaccine itself, (ii) while the responses as
measured, were in all senses the appropriate ones for resistance, there was no challenge of
vaccinated animals and second, the age of the vaccines would not allow for distinction
between a solid immune response induced by vaccination or natural resistance commonly
observed in animals under 1 year of age [3].
Msp2 is a highly immunodominant 36 kDa protein coded by a multigene family consisting of a
functional gene that codes for the amino and carboxyl ends and a variable number of
pseudogenes (5 in the St. Maries strain) [59] which recombine with the main gene, through
gene conversion, in a single expression site such that the protein is expressed as a new variant
in each cycle of rickettsemia, every 6–8 weeks [60]. msp2 pseudogenes code for hypervariable,
hydrophilic sequences containing highly immunogenic B cell epitopes which induce a new
immune response consequent to a new Msp2 variant [61]. The amino and carboxyl ends of the
Genome-Based Vaccinology Applied to Bovine Anaplasmosis
http://dx.doi.org/10.5772/intechopen.72637
51
protein are hydrophobic conserved segments inserted into the membrane of the rickettsia [62]
(and contain Th1 cell type epitopes that are preserved along different geographic strains) [29, 55].
Just like Msp1 and Msp1b, Msp2 was discovered through the neutralization of infection by
specific monoclonal antibodies and it was considered a vaccine candidate [28], this has not been
the case. While the hypervariable region of the protein contains a number of highly immuno-
genic type B cell epitopes, it has been recognized that antibody directed to these epitopes are
distractors of the immune response during the periodical appearance of Msp2 variants [60, 63].
Msp3 is a very immunogenic 86 k Da protein located on the surface of the rickettsia [28]. msp3
is also composed by a central hypervariable region coded by several pseudogenes which
recombine with the conserved amino and carboxyl ends [64, 65]. Based on previous studies
[64] and analysis of the published genome sequence, it is speculated that MSP2 and MSP3
originated from a common ancestor [66], and have diverged since that event. Sequence identity
between msp3 and msp2 pseudogenes is reduced, an average of 38%, identity within msp3
pseudogenes 68% and, within msp2 pseudogenes 78% [66, 67]. Immunologically, Msp2 and
Msp3 share epitopes recognized in vitro by CD4+ cells clones from vaccinated cattle [55].
Recombination of pseudogenes in a mosaic pattern also adds to the presentation of polymor-
phic antigens that, when resolved through 2D electrophoresis, are observed as a series of
antigens with the same molecular weight and different but very close isoelectric points [68].
Appearance of Msp2 and Msp3 variants in the persistently infected bovine gives rise to a more
complex situation with negative implications for immune protection. Though Msp3 induces
production of large amounts of antibodies [69], protection afforded is very limited [70]. Msp3
is known to cross-react with other rickettsiae such as A. ovis, Ehrlichia risticii, E. wengii, E. equi
and E. ruminantium, which make it unsuitable for specific A. marginale sero-diagnosis [71].
Msp4 is a 31 kDa protein, encoded by single highly conserved gene, msp4 [72]. Msp4 is also
present in A. marginale subsp. centralewith 83% identity in the nucleotide sequences and 91.7%
in the amino acid level [73]. To date, there is no solid evidence that Msp4 may be involved in
protection as, initial studies showed lack of recognition by sera of animals immunized with an
initial body membrane fraction [42], however when animals are immunized with a recombi-
nant Msp4 adjuvated with Iscometrix as adjuvant, there seems to induce an antibody response.
msp4 has been used as a base for phylogenetic studies which have shown that there are
variations in 168 bp and, of these, 39 bp show utility in parsimony analysis such that isolates
from several countries in the Americas can be grouped according to their geographic location
[50]. Msp4 is highly conserved over several Mexican isolates [9].
Msp5 is a highly conserved 19 kDa MW protein in A. marginale, A. marginale subsp. centrale
and A. phagocytophilum [23, 73–75]. Immunization with Msp5 induces the production of large
quantities of non-protective antibodies [69] so it is no suitable for vaccination. Animals natu-
rally infected with the rickettsia produce specific antibodies that can be found in recent and old
infections so the protein has been used successfully in a diagnostic competitive-ELISA test [76].
Despite the cross-reaction of antibody between A. marginale and A. marginale subsp. centrale at
the competitive-ELISA [74, 77], the test has been adopted as the standard for serologic diag-
nostic of bovine anaplasmosis.
Farm Animals Diseases, Recent Omic Trends and New Strategies of Treatment52
2.2. Type IV secretion system proteins
Secretion systems in bacteria are complex structures by which they communicate with its
environment. There are several secretion systems some which span both the inner membrane
(IM) and the outer membrane (OM), and those that span the OM [78]. Among several secretion
systems described in nature, type 4 secretion systems (T4SSs) have the unique ability to
mediate translocation of DNA (in addition to proteins) into bacterial or eukaryotic target cells.
T4SSs are found in both Gram-negative and Gram-positive bacteria and also in some archaea
[79]. Their most common role is to mediate the conjugation of plasmid DNA; thus, these
systems contribute to the spread of plasmid-borne antibiotic resistance genes. As the ability to
conjugate is a common bacterial trait, T4SSs are the most ubiquitous secretion systems in
nature. In addition, T4SSs are involved in bacterial pathogenesis in a few organisms, and they
mediate the secretion of transforming proteins inHelicobacter pylori, toxins in Bordetella pertussis
and other effector proteins required to support an intracellular lifestyle in bacteria such as
Legionella pneumophila [79].
Along with the publication of the first complete genome of A. marginale, and its annotation,
some real or putative homologous genes of T4SS were described in St. Maries genome [23].
Although many studies have been done about MSPs, so far, we still require other approaches
to find better vaccine candidates. An approach was shotgun sequencing of the proteins of a
membrane-enriched fraction of A. marginale, which induced an antibody response in naive
calves [80]. In this study, 25 immunoblot positive spots were sequenced and identified through
their annotation in the genome. Among the proteins identified VirB9, VirB10 and conjugal
transfer protein (CTP), were shown to stimulate an antibody response. Further studies using
the same membrane-enriched fractions for the immunization of young cattle showed that their
antibodies (IgG2) and Th cells reacted with the recombinant versions of CTP, VirB9 and VirB10
proteins [12]. In a more sophisticated study using far-Western blotting to identify protein
linkage between possible antigenic proteins, it was shown that VirB proteins, VirB9-1, VirB9-2
and Virb10 when physically linked, could stimulate a more specific and stronger immune
response than when used individually [81]. While presence of B cell epitopes is important in
any protein to be used as vaccine candidate, Th cell epitopes are also important as their
presence might determine the actual potential use of any antigen in a vaccine. An interesting
study, takes synthetic overlapping peptides from VirB9-1, VirB9-2 and VirB10 to test for the
presence of such epitopes [82]. T cells from six different MHC Class-II phenotypes outer
membrane fraction immunized animals were tested and as expected, it was observed that not
all animals reacted with peptides from all three TFSS proteins. While all six animals reacted to
the membrane fraction which contained all three VirB9-1, VirB9-2 and VirB10, some animals
did not react against rVirB9–1, others reacted poorly against rVirB9-2 or rVirB10 or against
only one or two of the overlapping synthetic peptides [82]. The differences in response of T
cells from these animals are explained in the context of the Class-II MHC molecules involved
in presentation of the epitopes. Interestingly, these authors restricted themselves to Holstein
cattle as the subjects to their studies yet, at least in Mexico and other Latin American countries,
Holstein cattle are used for milk production and most of them are reared under conditions
which preclude the contact with ticks.
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These studies clearly show that an immune response that fills the criteria for protection as
described is induced [11, 55], these authors though, fall short of proving that the induced
immunity is protective as there was no actual confrontation with the virulent live agent. In a
different study recombinant VirB9, Virb10 and Elongation Factor Tu (EF-Tu) were tested
against the sera of immunoprotected animals naturally infected with two A. marginale isolates
[83]. These works showed that while all experimentally infected cattle with the autologous
isolate had relevant antibodies (IgG2) against VirB9, VirB10 and EF-Tu, only 87% of the
animals naturally infected with a heterologous isolate reacted with the recombinant protein
by ELISA.
2.3. Outer membrane proteins
The outer membrane of bacteria delimits its structure and is the interface with the host cell.
Outer membrane proteins (OMPs) are key components of Gram-negative bacteria and because
are involved in adhesion and infection processes they are targeted on vaccine development.
Some effective attempts have been achieved using whole membrane fractions as immunogens
against bacterial diseases and due to their relevance OMPs from several pathogens have been
extensively studied and proposed as vaccine component. It is known that in addition to com-
position, OMPs show diversity in function too, but they share structural patterns. Usually,
regions with antigenic properties are located on the extracellular loops and show variable
composition, meanwhile residues in the transmembrane β-barrel show the highest conservation
[61, 84–86]. However, the use of individual components has only been partially successful
[86–92], although, it appears that the most relevant OMP antigens have not yet been identified.
High-throughput sequencing technologies are currently available and allow the identification of
several genes with potential important functions in the metabolism of the pathogen or in the
interaction with its surroundings. For example, from the complete genome of Anaplasma
marginale [23], the existence of additional outer membrane protein has been elucidated. Addi-
tionally, to Msp2 and Msp3, new members of pfam01617 family have been identified, and
designated as Omp 1-14. omp2, omp3 and omp6 genes are not transcribed in A. marginale-infected
erythrocytes, tick midgut and salivary glands, and the IDE8 tick cell line, while OMPs 1, 4, 7, 8, 9
and 11 were confirmed to be differentially expressed as proteins in those cell types [93]. Unlike
Msp2 and Msp3, these OMPs exhibit high conservation at sequence level as seen in the follow-
up of the infection and in comparative analyses with the St. Maries and Florida strain genomes,
which increases the possibility of choosing molecules capable of inducing a protective immune
response against bovine Anaplasmosis. Omp7 to Omp9 appear as tandem repeats with almost
75% amino acid identity, Omp10 is related to Omp7 to Omp9 with ~ 30% residues identity and
Omp6 is a truncated and it is not expressed version of Omp10. Omp7 to Omp9 are part of
protective outer membrane fraction and are highly expressed than Omp10 [23, 25, 93, 94].
In spite of the fact that none of these molecules has induced protection when is applied as an
individual protein, the importance of OMPs in protective immune response induction has been
revealed above all as complexes or associated with a membrane environment.
For example, protection against Leptospira was reached using OmpL1 and LipL41 expressed
simultaneously in the context of the E. colimembrane but, immunization with either membrane-
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associated protein or as part of a mixture of non-membrane-associated proteins was not pro-
tective [53, 95].
These results confirm the importance of OMPs in the infection process and the generation of a
protective immune response against pathogens and also reveal the interactions between OMPs
and other proteins as well as with their environment. However, production, solubilization and
purification of membrane-associated recombinant proteins is not easily achieved [96].
2.4. Hypothetical proteins
Genomic analyses of A. marginale have allowed identification of novel annotated proteins
whose function has not yet been determined, however, in silico analysis and predictions may
provide unrevealed information about immunogenic potential.
Some hypothetical proteins have been identified by structure prediction of β-barrel outer
membrane and orthology and bioinformatic analysis, such as Am1108, Am127, Am216,
Am202, Am936, Am854, Am368, Am854, Am1041, Am109 and Am1096. Some of these pro-
teins have been evaluated as recombinant molecules and recognized by IgG from immunized
animals with outer membranes protein, in this case, Am1108 and Am216 elicited specific T cell
response proliferation [13, 97]. On the other hand, cattle immunized with recombinant Am854
or Am936 developed higher bacteremia as compared to adjuvant-only controls and outer
membrane vaccinates after challenge [13].
The absence of a protective immune response after application of recombinant proteins pre-
sumably exposed to A. marginale, and therefore, with antigenic characteristics still seems to be
insufficient to develop prophylactic methods against bovine anaplasmosis.
Although genomic analyses have revealed valuable information about the composition of A.
marginale, it will be necessary to complement this knowledge with experimental evidence
based in other methods, such as proteomic and transcriptomic tools.
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